Abstracts tagged "anti-TNF therapy"

Abstract Number: 1721 • 2016 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis Evolution during 5 Years of Anti-Tnfalpha Treatment in Psoriatic Arthritis Patients: Preliminary Data
Augusta Ortolan¹, Giovanni Boschetti², Mariagrazia Lorenzin¹, Giulia Cherobin³, Leonardo Punzi³, Massimo Puato² and Roberta Ramonda³, ¹Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy, ²Clinica Medica III, Department of Medicine DIMED, University of Padova, Padova, Italy, ³Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Background/Purpose: Psoriatic Arthritis (PsA) is associated with increased morbility and mortality and an accelerated atherosclerosis. Influence of anti-TNFalpha treatment (a widely used therapy in PsA)…
Abstract Number: 2652 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis and Excess Mortality Associated with Treatments: a Systematic Review and Meta-Analysis
Manon Redondin¹, B Combe², Cécile Gaujoux-Viala³, Jacques Morel⁴ and Cédric Lukas⁵, ¹CHU Lapeyronie, University of Montpellier, France, ²Immuno-Rhumatologie, CHU Lapeyronie, University of Montpellier, France, ³CHU Nîmes, University of Montpellier, France, ⁴Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ⁵Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France
Background/Purpose: Patients with rheumatoid arthritis (RA) have a lower life expectancy than general population. The impact of RA treatments on global mortality is not…
Abstract Number: 252 • 2016 ACR/ARHP Annual Meeting
Cytokine Profiles of Korean Patients with Adult Onset Still’s Disease Treated with Biologic Agents
Seung Taek Song¹, SuMan Kang², Sung Won Lee³, Seoung Wan Nam², Hyukhee Kwon² and Dae-Hyun Yoo⁴, ¹Division of Rheumatology, Department of Internal Medicine, Cheongju St. Mary's Hospital, Cheongju, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ³Department of Rheumatology, Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Several studies have reported that pro-inflammatory cytokines including interleukin (IL)-1, IL-6,…
Abstract Number: 637 • 2016 ACR/ARHP Annual Meeting
Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs
Natalie Boytsov¹, George W. Reed², Leslie R Harrold^2,3, Xiang Zhang¹, Carol L Gaich¹, Cynthia J Larmore¹, Ying Shan², S Rebello⁴ and Andre B. Araujo¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Corrona, LLC, Southborough, MA, ³UMass Medical School, Worcester, MA, ⁴Epidemiology, Corrona, Southborough, MA
Background/Purpose: The purpose of this study was to describe biologic initiation patterns over a 1-year follow-up period in rheumatoid arthritis (RA) patients with moderate…
Abstract Number: 1736 • 2016 ACR/ARHP Annual Meeting
Efficacy of TNF Inhibitors in Axial Spondyloarthritis According to the Presence of Objective Signs of Inflammation: A Multicentric Retrospective Study
Celine Vidal¹, Cédric Lukas², Bernard Combe³, Francis Berenbaum⁴, Christian Jorgensen⁵, Jeremie Sellam⁶ and Jacques Morel⁷, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ³Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁴Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁵Inserm u844, Unite ImmunoRhumatologie Therapeutique, Montpellier, France, ⁶Rheumatology, Saint-Antoine Hospital, Paris, France, ⁷Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France
Background/Purpose: TNF inhibitors (TNFi) are effective treatment in radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA). Nr-axSpA have lower response rate in case of absence…
Abstract Number: 2718 • 2016 ACR/ARHP Annual Meeting
Plasma Levels of the M2 Macrophage Markers, CD163 and CD206, Changes Reversely and Soluble CD163 Is Associated with Disease Activity in Spondyloarthritis
Line Dam Heftdal^1,2, René Østgård^3,4, Malene Hvid^3,5, Bent Deleuran^2,3,5, Holger Jon Møller⁵ and Stinne Greisen^2,3, ¹Department of Biomedicine, Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Biomedicine, Aarhus University, Aarhus, Denmark, ⁴Department of Rheumatology, Regional Hospital Silkeborg, Silkeborg, Denmark, ⁵Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: Spondyloarthritis (SpA) covers a group of interrelated auto-inflammatory disorders where TNFa is a central mediator of disease. T cells and macrophages are abundant in…
Abstract Number: 433 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Latent Tuberculosis and Hepatitis B Found after Systematic Screening of Patients Starting with Biological Therapy in a Low-Endemic Area
Marin de Jong^1,2, Danielle Roosen¹, Andy Peters¹, Valerie Verstraeten³, Marieke Pierik¹ and A. van Tubergen⁴, ¹Department of Internal Medicine, division of Gastroenterology, Maastricht University Medical Centre, Maastricht, Netherlands, ²NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, Netherlands, ³Department of Dermatology, Maastricht University Medical Centre, Maastricht, Netherlands, ⁴Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Biologicals are a powerful treatment option for moderate to severe immune-mediated inflammatory diseases (IMID). Since biologicals modulate the immune system, the risk for reactivation…
Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Theodora Bejan-Angoulvant¹, David Ternant², Fadela Daoued³, Frédéric Medina³, Louis Bernard⁴, Saloua Mammou³, Gilles Paintaud² and Denis Mulleman⁵, ¹Service de Pharmacologie Clinique, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ²Laboratoire de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ³Service de Rhumatologie, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁴Service des Maladies Infectieuses, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁵Service de Rhumatologie, Rheumatology department, François-Rabelais University, CNRS 7292, CHRU de Tours, Tours, France
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…
Abstract Number: 2005 • 2016 ACR/ARHP Annual Meeting
Exploring the Window of Opportunity for Drug-Free Clinical Remission in Patients with Active, Very Early Peripheral Spondyloarthritis
Philippe Carron¹, Gaëlle Varkas², Heleen Cypers², Liesbet Van Praet¹, Dirk Elewaut² and Filip van Den Bosch¹, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium
Background/Purpose: To evaluate drug-free sustained clinical remission and clinical relapse after induction therapy with golimumab in patients with active peripheral Spondyloarthritis (pSpA) in a very…
Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting
The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Mark Berman¹, Daphna Paran¹, Yonatan Wolman¹ and Ori Elkayam², ¹Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…
Abstract Number: 442 • 2016 ACR/ARHP Annual Meeting
Comparison of Adherence and Dosing Interval of Subcutaneous Anti-TNF Biologics in Inflammatory Arthritis from a Canadian Administrative Database.
Peter Bhoi¹, Louis Bessette², Mary Bell³, Cathy Tkaczyk⁴, Francois Nantel⁵ and Karina Maslova¹, ¹Janssen Inc., Toronto, ON, Canada, ²Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁵19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Subcutaneous (SC) anti-TNF agents such as Golimumab (GLM) Adalimumab (ADA), Etanercept (ETA) and Certolizumab pegol (CZP) Index period was from January 1, 2010 -…
Abstract Number: 699 • 2016 ACR/ARHP Annual Meeting
In Contrast to Men, Women with Nonradiographic Axial Spondyloarthritis Have Lower Response Rates to TNF Inhibitors Than Women with Ankylosing Spondylitis
Adrian Ciurea¹, Monika Hebeisen², Ulrich Weber^3,4, Giorgio Tamborrini⁵, Raphael Micheroli¹, Lukas Wildi¹, Pascal Zufferey⁶, Michael J. Nissen⁷, Peter M. Villiger⁸, Juerg Bernhard⁹, Désirée van der Heijde¹⁰, RBM Landewé^11,12, Almut Scherer² and Pascale Exer¹³, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁴Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland, ⁶Rheumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁷Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁸Rheumatology, Clinical immunology & Alllergology, University Hospital Bern, Bern, Switzerland, ⁹Rheumatology Center, Buergerspital, Solothurn, Switzerland, ¹⁰Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹¹Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹²Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands, ¹³Private rheumatology practice, Basel, Switzerland
Background/Purpose: Response to tumor necrosis factor inhibition (TNFi) has been shown to be similar in nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) in patients…
Abstract Number: 2048 • 2016 ACR/ARHP Annual Meeting
Evaluating Transfer of Certolizumab Pegol into Breast Milk: Results from a Prospective, Postmarketing, Multicenter Pharmacokinetic Study
Megan E. B. Clowse¹, Frauke Förger², Caroline Hwang³, John Thorp⁴, Radboud J. E. M. Dolhain⁵, Astrid van Tubergen⁶, Laura Shaughnessy⁷, Jeff Simpson⁸, Marie Teil⁹, Nathalie Toublanc¹⁰, Maggie Wang⁸ and Thomas W. Hale¹¹, ¹Rheumatology, Duke University School of Medicine, Durham, NC, ²Rheumatology, Clinical Immunology and Allergology, Inselspital University Hospital of Bern, Bern, Switzerland, ³Keck Hospital of USC, Los Angeles, CA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Rheumatology, University Medical Center Rotterdam, Rotterdam, Netherlands, ⁶Maastricht University Medical Center, Maastricht, Netherlands, ⁷8010 Arco Corporate Drive, Sui, UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹Texas Tech University School of Medicine, Amarillo, TX
Background/Purpose: Women with chronic inflammatory diseases, including rheumatic diseases and Crohn’s disease (CD), face uncertainty regarding the safety of the use of biologics during breastfeeding.…
Abstract Number: 2970 • 2016 ACR/ARHP Annual Meeting
Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database
Bertrand Lioger^1,2, Fanny Hennekinne¹, Marie-Sara Agier³, Annie-Pierre Jonville-Bera^3,4 and François Maillot^1,5, ¹Internal Medicine, Tours University Hospital, Tours, France, ²GICC UMR 7292, University François Rabelais, Tours, France, ³Clinical Pharmacology, Tours University Hospital, Tours, France, ⁴Regional Pharmacovigilance Center, Tours University Hospital, Tours, France, ⁵INSERM U1069, University François Rabelais, Tours, France
Background/Purpose: Immunological classes of adverse events (AEs), including the immune related AEs and the paradoxical effects, have emerged with the used of biologics. Among them,…
Abstract Number: 483 • 2016 ACR/ARHP Annual Meeting
Non-Steroidal Anti-Inflammatory Drugs Are More Beneficial Than Anti-Tnfα Drugs on the Radiographic Damage in Arthritis: A Study in Adjuvant Induced Arthritis
Frank Verhoeven¹, Clément Prati², Perle Totoson¹, Romani Bordy³, Daniel Wendling⁴ and Céline Demougeot¹, ¹EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon, France, ²FDE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France, ³EA 4267 FDE, FHU increase, BESANCON, France, ⁴Service de Rhumatologie, CHU Jean Minjoz, Besancon, France
Background/Purpose: The management of the chronic inflammatory rheumatisms has dramatically evolved in the last decade with a concept of “treat to target”. The theory of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.